BRAF and colorectal carcinoma: In recent CRC clinical FIRE-3 trials, RAS, BRAF V600E, and SMAD4 mutations were identified as poor prognostic biomarkers in patients, whereas improved outcome for cetuximab efficacy was observed for BRAF non-V600E mutation [38].